Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
OCS | US
-1.08
-3.88%
Healthcare
Biotechnology
30/06/2024
23/04/2026
26.77
27.85
28.04
26.45
Oculis Holding AG a clinical-stage biopharmaceutical company develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01 a topical dexamethasone formulation which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02 a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca or dry eye disease; and OCS-05 a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders such as glaucoma diabetic retinopathy geographic atrophy and neurotrophic keratitis. The company is based in Zug Switzerland.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Weakness based on declining price with high volume
Price Below SMA10D
Smallcap (300M - 2B USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
38.3%1 month
42.2%3 months
42.4%6 months
44.0%-
-
4.49
0.01
0.01
-3.47
-
-
-62.84M
1.12B
1.12B
-
-9.18K
-
-2.00
-58.12
0.61
0.06
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
2.86
Range1M
5.29
Range3M
6.66
Rel. volume
1.39
Price X volume
11.11M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Capricor Therapeutics Inc | CAPR | Biotechnology | 33.86 | 1.20B | -3.26% | n/a | 45.32% |
| NRIX | NRIX | Biotechnology | 16.57 | 1.17B | -0.36% | n/a | 7.20% |
| Progenitor Inc | PGEN | Biotechnology | 3.96 | 1.16B | 0.00% | n/a | 14.69% |
| AbCellera Biologics Inc | ABCL | Biotechnology | 4.05 | 1.14B | -0.74% | n/a | 6.49% |
| Pharming Group N.V. | PHAR | Biotechnology | 16.64 | 1.13B | -2.58% | n/a | 63.43% |
| Wave Life Sciences Ltd | WVE | Biotechnology | 7.31 | 1.11B | -0.95% | n/a | 656.70% |
| VIRIDIAN THERAPEUTICS ORS INC | VRDN | Biotechnology | 14.23 | 1.09B | -0.70% | n/a | 3.96% |
| MoonLake Immunotherapeutics | MLTX | Biotechnology | 16.93 | 1.06B | -1.68% | n/a | 0.64% |
| Biohaven Pharmaceutical Holding Company Ltd | BHVN | Biotechnology | 10.52 | 1.06B | -1.50% | n/a | 7.75% |
| Iovance Biotherapeutics Inc | IOVA | Biotechnology | 3.48 | 1.06B | -1.42% | n/a | 10.63% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Winnebago Industries Inc | WGO | Recreational Vehicles | 32.64 | 945.09M | 0.15% | 22.53 | 56.33% |
| Janus International Group Inc. | JBI | Building Products & Equipment | 5.37 | 780.38M | -2.01% | 11.62 | 116.21% |
| Fox Factory Holding Corp | FOXF | Recreational Vehicles | 17.3 | 721.12M | 0.41% | 42.05 | 64.69% |
| Latham Group Inc. | SWIM | Building Products & Equipment | 6.02 | 695.77M | 0.17% | 65.18 | 77.00% |
| Ennis Inc | EBF | Building Products & Equipment | 20.59 | 535.42M | 1.28% | 13.28 | 2.28% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 26.34 | 526.56M | 4.48% | n/a | 1.50% |
| MCBC Holdings Inc | MCFT | Recreational Vehicles | 23.74 | 394.26M | 2.50% | 34.27 | 26.82% |
| Camping World Holdings Inc | CWH | Recreational Vehicles | 6.9 | 311.39M | -2.54% | n/a | 3644.76% |
| ACCO Brands Corporation | ACCO | Building Products & Equipment | 3.25 | 311.34M | -2.11% | n/a | 174.23% |
| Marine Products Corporation | MPX | Recreational Vehicles | 8.07 | 280.17M | 2.15% | 13.23 | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.47 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.49 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 42.36 | - | Lower Risk |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 1.12B | - | Emerging |